Rethinking Oncologic Treatment Strategies with Interleukin-2

High-dose recombinant human IL-2 (rhIL-2, aldesleukin) emerged as an important treatment option for selected patients with metastatic melanoma and metastatic renal cell carcinoma, producing durable and long-lasting antitumor responses in a small fraction of patients and heralding the potential of ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Brian, Takebe, Naoko, Andrews, Omozusi, Makena, Monish Ram, Chen, Alice P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177415/
https://www.ncbi.nlm.nih.gov/pubmed/37174716
http://dx.doi.org/10.3390/cells12091316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177415/
https://www.ncbi.nlm.nih.gov/pubmed/37174716
http://dx.doi.org/10.3390/cells12091316

Ejemplares similares